Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7652W HIGH $3.54
Volume
35.11 K
Value Traded
1.32 M
Short % Float
10.87%
+2.13%Week
-43.75%1 Month
-50.52%3 Month
-20%6 Month
-66.32%5 Year
-84.25%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
90.99 M
EPS (TTM)
-0.28
P/E Ratio
-
Ent. Value
34.14 M
Total Shares
63.41 M
Float Shares
50.62 M
Insiders
20.17%
Institutions
58.59%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
EQ Catalyst Timeline
Dated clinical, regulatory and corporate events for Equillium, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Equillium, Inc.
327Total events
13Upcoming
91Tier-1 (high impact)
2018 to 2029Coverage
Upcoming catalysts 2
Event history 50
●Poster PresentationEQ504Presentation
Poster presentation of EQ504 preclinical data at 50th Anniversary La Jolla Immunology Conference
ulcerative colitissource ↗
▲Trial Authorization (CTA / IND)EQ504Ex-US Regulatory
TGA clearance under CTN scheme for Phase 1 trial of EQ504
ulcerative colitissource ↗
▲Ethics Committee ApprovalEQ504Trial
HREC approval for Phase 1 trial of EQ504
ulcerative colitissource ↗
●Poster PresentationEQ504Presentation
Poster P.43 (Poster 89): Selective AhR Activation Suppresses Epithelial Chemokine Production and Promotes Barrier Repair in Translational Models of Ulcerative Colitis
ulcerative colitissource ↗
●IND Enabling CompleteEQ504Preclinical
IND-enabling development activities initiated for EQ504 as inhaled therapy
inflammatory lung diseasessource ↗
●IND Enabling CompleteEQ302Preclinical
IND-enabling development activities initiated for EQ302
celiac diseasesource ↗
◆Oral PresentationPresentation
Equillium management presenting at Oppenheimer's 2026 Innovation on the Island Event
◆Poster PresentationEQ504Presentation
Poster presentation: EQ504, a Potent AhR Modulator, Promotes Epithelial Repair and Barrier Restoration Compared to Clinically Validated AhR Agonists
ulcerative colitissource ↗
◆Poster PresentationEQ504Presentation
Poster presentation: EQ504: A Novel AhR Modulator That Promotes Immune Tolerance Through Il-10 and Il-22 Cytokine Release
ulcerative colitissource ↗
◆Trial InitiationEQ504Trial
Phase 1 proof-of-mechanism study initiation expected mid-2026
ulcerative colitissource ↗
▲Oral PresentationEQ504Presentation
Presented two EQ504 abstracts at IMMUNOLOGY2026
ulcerative colitissource ↗
◆Oral PresentationPresentation
Equillium management to participate in fireside chat at 38th Annual Roth Conference
▼Equity OfferingCorporate
Equillium announces $35 million PIPE financing with RA Capital Management
◆Oral PresentationPresentation
Fireside chat at Leerink Partners 2026 Global Healthcare Conference
◆Timing GuidanceItolizumabPresentation
Potential BLA submission for itolizumab in aGVHD
first-line acute graft-versus-host diseasesource ↗
◆Oral PresentationPresentation
Equillium management to participate in Jefferies Global Healthcare Conference in London
●Runway Guidance UpdateCorporate
Initial tranche of $30 million expected to fund operations through 2027
◆Oral PresentationPresentation
Equillium management to present at Stifel Healthcare Conference
◆Oral PresentationEQ504Presentation
Virtual KOL event on ulcerative colitis and EQ504
ulcerative colitissource ↗
▼Equity OfferingCorporate
Closed private placement of up to $50 million; initial tranche of $30 million
◆FDA Feedback ReceivedItolizumabFDA Meeting
FDA meeting to discuss Accelerated Approval pathway
first-line acute graft-versus-host diseasesource ↗
▼FDA Feedback ReceivedItolizumabFDA Meeting
FDA Type D meeting feedback received; declined Breakthrough Therapy and Accelerated Approval
acute graft-versus-host disease (aGVHD)source ↗
▼Breakthrough Therapy DesignationItolizumabDesignation
Breakthrough Therapy designation declined by FDA
acute graft-versus-host disease (aGVHD)source ↗
▼Trial DiscontinuedItolizumabTrial
Accelerated closure of EQUATOR study planned
acute graft-versus-host disease (aGVHD)source ↗
◆Topline ReadoutItolizumabClinical Data
Topline data from Phase 3 EQUATOR study in first-line aGVHD
first-line acute graft-versus-host diseasesource ↗
◆Breakthrough Therapy DesignationItolizumabDesignation
Breakthrough Therapy designation request submitted to FDA
first-line acute graft-versus-host diseasesource ↗
●Oral PresentationEQ302Presentation
Data presented on dual and synergistic signaling of IL-15 and IL-21 targets of EQ302
◆Topline ReadoutItolizumabClinical Data
Potential acceleration of topline data from EQUATOR study to Q1 2025
acute graft-versus-host diseasesource ↗
◆Trial InitiationEQ101Trial
Initiate Phase 2b dose optimization study in alopecia areata
alopecia areatasource ↗
●Trial CompletionItolizumabTrial
Phase 2 ulcerative colitis study completed by Biocon
ulcerative colitissource ↗
●Enrollment UpdateItolizumabTrial
Enrollment reduced to ~150 patients
acute graft-versus-host diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How EQ actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-06 | EQ504 | Pre-clinical data presentation | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D35 / 100
Pipeline Score
$15M
Pipeline Value
Overvalued
Valuation Signal
4
Drugs Scored
0.2x
rNPV / MCap
Top 54%
Micro Cap(rank 356 of 658)
Percentile Rank
Equillium, Inc. faces pipeline headwinds (35/100), with $307M risk-adjusted pipeline value, led by EQ001 in Asthma (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EQ001 Monoclonal antibodyCompletedNCT03763318 | Acute-graft-versus-host Disease | Phase 1 | COMPLETED | 30 | Nov 21, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every EQ program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| itolizumab | acute graft-versus-host disease | Phase 3 | 2025-03-27 | duration of CR: median 336, p value 0.017; failure free survival: median 154, p value 0.043; CR at Day 99: patients itolizumab 35, patients placebo 22, p value 0.035; overall survival trend: mortality itolizumab 19, mortality placebo 25Read More | Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights Announced topline data from the Phase 3 EQUATOR study in first-line acute graft-versus-host disease BreakRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Zedelmayer ChristineOfficer (Sr. Vice President and COO) | Option | 14,584 77,170 held | $0.79 | 06/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in EQ
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| AFFINITY ASSET ADVISORS, LLC | 0.6 % (500 %) | 13.12 M | 4.10 M | 234.34% ( 2.87 M) |
EQ Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EQ ranks across every disease it competes in
Competitive Position is a premium feature
See how EQ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEQ News
EQ▼ -1.4%today
Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference
Equillium, Inc. announced the presentation of new preclinical data for its EQ504 program at the 50th Anniversary La Jolla Immunology Conference. The data highlights EQ504's ability to preserve barrier integrity and reduce inflammation, which is particularly relevant for treating ulcerative colitis. The poster presentation is scheduled for October 6, 2026.
Read more →EQ▼ -1.4%today
Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
Equillium, Inc. has received regulatory approval in Australia to initiate a Phase 1 clinical trial for EQ504, a novel therapy aimed at treating severe autoimmune disorders. The trial will assess safety, tolerability, and pharmacokinetics in healthy participants, with dosing expected to start in early November 2026. If successful, a subsequent proof-of-concept study for ulcerative colitis may follow in 2027.
Read more →EQEquillium Announces Poster Presentations at the 7th International AHR Conference
Equillium, Inc. announced the presentation of new preclinical data for its EQ504 program at the 7th International AHR Conference in Porto, Portugal. The data highlights EQ504's multi-modal activity in promoting epithelial barrier repair and modulating immune responses, suggesting its potential in treating ulcerative colitis. The findings contribute to the understanding of selective AhR modulation as a therapeutic strategy.
Read more →EQ▼ -9.5%on this news
Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum
Equillium, Inc. will participate in Stifel's 2026 Virtual Immunology and Inflammation Forum on September 23, 2026. The management team will conduct a fireside chat and is available for investor meetings. A live webcast of the event will be accessible, with a replay available for 45 days post-conference.
Read more →EQEquillium to Participate in Upcoming Investor Conferences
Equillium, Inc. announced its participation in two upcoming investor conferences. The Cantor Global Healthcare Conference will feature a fireside chat and one-on-one meetings on September 9, 2026. The H.C. Wainwright 28th Annual Global Investment Conference will include a company presentation and meetings on September 14, 2026. Management will be available for investor interactions.
Read more →EQ▲ +17.4%on this news
Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Equillium, Inc. reported its Q2 2026 financial results, highlighting progress on EQ504, an aryl hydrocarbon receptor modulator. The Phase 1 proof-of-mechanism study is set to begin in Q4 2026, with topline data expected in mid-2027. The company has $57.2 million in cash, projected to fund operations until 2029. Recent developments include IND-enabling activities for EQ504 and EQ302.
Read more →EQ▲ +11.5%on this news
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 2, 2026
Equillium, Inc. announced the grant of nonstatutory stock options to a new employee under its 2024 Inducement Plan. The award consists of 145,000 shares with an exercise price of $3.08, vesting over four years. This grant is in accordance with Nasdaq Listing Rule 5635(c)(4), reflecting the company's commitment to attracting talent.
Read more →EQ▲ +8%on this news
Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
Equillium, Inc. announced its participation in the 2026 Jefferies Global Healthcare Conference, scheduled for June 3, 2026. The management team will engage in a fireside chat and is available for investor meetings. This highlights Equillium's commitment to connecting with stakeholders and promoting its innovative therapies for autoimmune and inflammatory disorders.
Read more →EQ▲ +16.7%on this news· ran to +31% by day 3
Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis
Equillium, Inc. is set to host a virtual investor event on May 27, 2026, led by Chief Scientific Officer Stephen Connelly, to present new preclinical data regarding the Aryl Hydrocarbon Receptor (AhR) and its interaction with miR-124. The session will discuss the implications of these findings for therapeutic development in autoimmune and inflammatory disorders. Notably, the webinar aims to clarify the complex relationship between AhR activation and miR-124 induction, which has been controversial in previous studies.
Read more →EQEquillium Reports First Quarter 2026 Financial Results and Corporate Highlights
Equillium has reported its financial performance for Q1 2026, revealing a net loss of $5.3 million, improved from the prior year's loss. The company is preparing to initiate a Phase 1 proof-of-mechanism study for its drug candidate EQ504, targeting inflammatory diseases, with data expected to be released about six months post-initiation. Financial resources are projected to sustain operations until 2029, enhanced by a recent $35 million financing. Furthermore, Equillium has strengthened its leadership team with the appointment of Dr. Snehal Naik as Chief Development Officer to oversee clinical development and strategy.
Read more →EQEquillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
Equillium, Inc. announced the grant of 800,000 stock options to two new employees as part of its 2024 Inducement Plan. The options have an exercise price of $2.08, which is equal to the company's closing stock price on the grant date. The vesting schedule spans four years, contingent on continued employment.
Read more →EQEquillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Equillium, Inc. announced the grant of inducement stock options totaling 800,000 shares to two new employees, in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $2.08 and will vest over four years. The company's lead candidate, EQ504, is designed to treat severe autoimmune and inflammatory disorders such as ulcerative colitis and lung diseases. The announcement underscores Equillium's growth trajectory as well as the potential challenges that lie ahead, aligned with industry-wide risks in clinical development.
Read more →EQ▲ +7%on this news
Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event
Equillium, Inc. will present at Oppenheimer's 2026 Innovation on the Island Event on April 28, 2026. The management team will also be available for meetings with registered investors. The company focuses on developing novel therapies for autoimmune and inflammatory disorders, with EQ504 as their lead candidate.
Read more →EQ▼ -6.2%on this news
Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists
Equillium, Inc. announced that new preclinical data for EQ504 will be presented at IMMUNOLOGY2026™, the annual meeting of the American Association of Immunologists. The presentations will focus on EQ504's role as a potent AhR modulator, which may enhance immune responses and promote mucosal healing in conditions like ulcerative colitis. The event will take place in Boston from April 15-19, 2026.
Read more →EQEquillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 2, 2026
Equillium, Inc. announced the grant of stock options to a new employee under its 2024 Inducement Plan. The award consists of 32,000 nonstatutory stock options with an exercise price of $2.04, vesting over four years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to support the company's growth in developing therapies for autoimmune disorders.
Read more →EQEquillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights
Equillium, Inc. reported its financial results for Q4 and full year 2025, highlighting a transformative year focused on advancing EQ504. The company plans to initiate a Phase 1 study of EQ504 in mid-2026, with expectations of data six months later. Despite no revenue in 2025, Equillium's cash position is projected to support operations until 2029.
Read more →EQEquillium to Participate in the 38th Annual Roth Conference
Equillium, Inc. will participate in the 38th Annual Roth Conference on March 23, 2026. The management team will be available for investor meetings, showcasing their commitment to investor engagement. The company focuses on developing therapies for severe autoimmune and inflammatory disorders, with their lead candidate EQ504 showing promise in treating conditions like ulcerative colitis.
Read more →EQ▲ +19.3%on this newsshared move
Equillium Announces $35 Million Financing with RA Capital Management
Equillium, Inc. has announced a $35 million financing agreement with RA Capital Management to support the clinical development of its investigational therapy EQ504. The funds will help extend the company's cash runway into 2029 and facilitate the advancement of EQ504, which targets ulcerative colitis. This financing is seen as a strong endorsement of Equillium's strategy.
Read more →EQEquillium to Participate in the Leerink Partners 2026 Global Healthcare Conference
Equillium, Inc. announced its participation in the Leerink Partners 2026 Global Healthcare Conference, scheduled for March 11, 2026. The management team will conduct a fireside chat and is available for investor meetings. The company focuses on novel therapies for severe autoimmune and inflammatory disorders, with its lead candidate EQ504 showing promise in treating conditions like ulcerative colitis.
Read more →About Equillium, Inc.
Headquarters2223 AVENIDA DE LA PLAYA, LA JOLLA, CA, 92037
BIOPHARMAWATCH ELITE PLUS
Trade the next EQ catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime